Guidelines for monitoring thyroid function in congenital hypothyroidism (CH) are published by the American Academy of Pediatrics, the European Society for Paediatric Endocrinology and the UK Newborn Screening Programme Centre. The fact that the recommendations are not uniform reflects management uncertainty. In addition, clinical care may not always be informed by these guidelines. Recent studies suggest that more frequent monitoring is indicated in some infants. Monitoring to identify delayed thyroid stimulating hormone (TSH) rise is indicated in pre-term, low birth weight and sick full-term newborns. Monitoring thyroid function in infants with CH monthly after normalisation of TSH until six months of age, and every one to two months between six and 12 months of age, will decrease exposure to suboptimal thyroid hormone levels. Assessment for permanency of hypothyroidism should be done only in children in which there is likelihood of resolution and not earlier than three years of age. In some instances, when TSH elevations persist after normalisation of the free thyroxine, it may be reasonable to try combined therapy with triiodothyronine.
severe CH cases were transient in the older cohort and only 4 % of the severe cases were transient in the younger cohort; 43 % of the mild CH cases were transient in the older cohort and 36 % of the mild cases were transient in the younger cohort. Unfortunately, there are no criteria to discriminate between children who will have transient and those who will have persistent hypothyroidism. Because there are no long-term follow-up studies on outcomes with and without treatment, it is unclear whether patients benefit from treatment. In the absence of essential long-term follow-up data, patients with mild CH and delayed TSH rise are managed similarly to those with severe CH, with the same treatment and monitoring plan.
Monitoring Thyroid Function in Newborns at Risk of Developing Delayed Thyroid Stimulating Hormone Rise
Delayed TSH rise is defined as a normal TSH level with low T4 level on a newborn's initial screening, with detection of elevated TSH and persistent low T4 on subsequent screening. Since newborn screening programmes differ in their screening methods and indications for repeat screening, some programmes will miss this pattern. Screening programmes using a primary TSH test that do not routinely obtain a second sample will miss this pattern of abnormal TFTs.
The current American Academy of Pediatrics (AAP) guidelines include measurement of TFTs at two weeks if the initial screening has shown low T4 and normal TSH in pre-term infants, low birth weight infants and sick full-term newborns. 2 There are no recommendations regarding the initial method and timing of screening to ensure that those 'delayed TSH rise' babies will be identified. Data from the Massachusetts Newborn Screening Program in 2000 suggested that delayed TSH rise is more common in low birth weight babies. 7 A few possible aetiologies have been suggested to explain delayed TSH rise in sick premature infants. One possible explanation is an attenuated response of the hypothalamic-pituitary-thyroid axis secondary to its immaturity. Another possible cause is an increased incidence of sick euthyroid syndrome. Some premature and sick babies are exposed to iodine and receive dopamine, both known to suppress TSH secretion.
There are insufficient data to distinguish between the different possible aetiologies. The long-term outcomes of subclinical hypothyroidism with mildly elevated TSH and normal T4 remains unclear. The finding that, in patients with delayed TSH rise, TFTs may normalise without treatment raises the question of whether or not treatment is indicated.
With increasing numbers of premature infants surviving, larger numbers of children with delayed TSH rise can be expected.
Additional studies are required to determine the need for treatment and establish appropriate guidelines for the monitoring of TFTs in at-risk newborns.
Monitoring Thyroid Function in Newborns Diagnosed with Congenital Hypothyroidism During the First Three Years of Life
The current AAP guidelines include measurement of T4 and TSH two to four weeks after starting treatment, every one to two months during the first six months of life, every three to four months between six months and three years of age, and every six to 12 months until growth is complete. More frequent testing is suggested when non-adherence to treatment is suspected or when TFTs are abnormal.
Furthermore, TFTs should be repeated four weeks after any change in levothyroxine (L-T4) dose. 2 The European Society for Paediatric Endocrinology (ESPE) recommends monitoring TFTs every one to two weeks after initiation of treatment until T4 and TSH have normalised, but does not give guidelines for long-term monitoring. 10 While the AAP recommends repeat TFTs to be carried out two to four weeks after initiation of therapy, the UK guidelines recommend that the first follow-up should be within 14 days, and the ESPE guidelines recommend follow-up within 7-14 days of treatment initiation. The shorter interval in the ESPE guidelines is based on a study showing that 7.4 % of infants started on a dose of 25 μg of L-T4 had subnormal free T4 (fT4) seven days after treatment initiation. The percentage was lower with higher initial doses (5.1 % with a 37.5 μg dose and 0 % with a 50 μg dose). 11 The shorter interval is important for monitoring adherence to treatment and verifying the adequacy of the dose and delivery method, but it is less important if the AAP recommendation of a high initial dose of 10-15 μg/kg of body weight is followed.
A recent paper published by our group suggests monthly monitoring during the first year of life is needed to maintain fT4 levels in the upper half of the normal range and TSH in the normal range. 12 This retrospective study evaluated 70 children with CH for initial TSH levels, frequency of follow-up, changes in dose and TFTs during the first year of life. Age-appropriate normal ranges for TFT levels were used until three months of age, after which adult normal ranges were used. TFTs were regarded as abnormal if total T4 (tT4) or fT4 were not in the upper half of the normal range, or if TSH was not in the normal range.
Subjects had TFTs carried out monthly for the first six months of life and every one to two months between six and 12 months of age.
Criteria indicating the need for monthly monitoring included:
• change in dose within one month of a previous visit;
• total T4 or fT4 levels not in upper half of normal range within one month of a previous visit;
• TSH level of 5-10 μU/ml (less than twice the upper limit of normal)
within one month of a previous visit associated with tT4/fT4 not in the upper half of normal range (to avoid inclusion of subjects with transient resistance to TSH sometimes reported in the first year of life in children with CH);
• TSH >10 μU/ml (more than twice the upper limit of normal) within one month of a previous visit, regardless of tT4/fT4 levels; and
• TSH <0.1 μU/ml. Predictors of the need for monthly monitoring in the second six months of life included higher TSH and lower tT4 at diagnosis.
Unfortunately, the overlap between the groups was such that monthly monitoring during the first year of life would seem to be necessary for all children diagnosed with CH, until further studies are available.
These recommendations are closer to the previous AAP guidelines, published in 1993, which stated that TFTs should be monitored every one to two months during the first year of life, every two to three months between one and three years of age, and every three to 12 months until growth is complete. 14 The frequency of monitoring of TFTs after three years of age has not been well studied, as fewer data are available regarding long-term outcomes of children with CH with suboptimal treatment after the age of three. The current AAP guidelines recommend monitoring TFTs every six to 12 months until growth is complete.
Assessing Permanency of Hypothyroidism
Given the deleterious effect of under-treatment of CH during the first years of life, over-diagnosis is the inevitable price to pay for treating patients with transient hypothyroidism. To identify this subpopulation, children should be taken off thyroid replacement therapy for a trial period as soon as it is thought that a short period of untreated hypothyroidism will not have a significant effect on the developing brain. Determining the aetiology of the child's hypothyroidism may be helpful in deciding whether or not to temporarily withdraw replacement therapy.
Persistent Elevated Levels of Thyroid Stimulating Hormone
Levels of TSH remain elevated in some children with CH despite appropriate L-T4 treatment and normalisation of serum fT4 and tT4 levels. In this subpopulation, supraphysiologic T4 levels are required to suppress TSH levels. The precise mechanism is unclear but, in cases where adherence to treatment is not in question, it is thought 
Genetic Causes of Congenital Hypothyroidism
Eighty-five per cent of cases of CH are attributable to thyroid dysgenesis and 2 % of these are familial. Most of the genes implicated in thyroid dysgenesis are associated with phenotypic syndromes and would typically be diagnosed as a result of the associated anomalies. 
From Guidelines to Practice
A recent study in the UK compared the national practice of early management of CH with the latest available European and UK guidelines. 17 The 
Summary
Adequate and timely follow-up of CH is critical for optimising outcomes. Guidelines for follow-up should be revised frequently to accommodate new information. Presently, there are differences between the guidelines of the AAP, ESPE and UK thyroid study groups.
Further differences arise in practice due to a lack of adherence to the recommendations. For optimum patient care, it would be important to ensure that uniform evidence-based guidelines are developed and that they are followed in practice. n
